BR9106258A - Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideo - Google Patents
Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideoInfo
- Publication number
- BR9106258A BR9106258A BR919106258A BR9106258A BR9106258A BR 9106258 A BR9106258 A BR 9106258A BR 919106258 A BR919106258 A BR 919106258A BR 9106258 A BR9106258 A BR 9106258A BR 9106258 A BR9106258 A BR 9106258A
- Authority
- BR
- Brazil
- Prior art keywords
- oligonucleotide
- interfer
- replication
- modulate
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49709090A | 1990-03-21 | 1990-03-21 | |
PCT/US1991/001822 WO1991014436A1 (en) | 1990-03-21 | 1991-03-19 | Reagents and methods for modulating gene expression through rna mimicry |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9106258A true BR9106258A (pt) | 1993-04-06 |
Family
ID=23975415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR919106258A BR9106258A (pt) | 1990-03-21 | 1991-03-19 | Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideo |
Country Status (10)
Country | Link |
---|---|
US (2) | US5736294A (pt) |
EP (1) | EP0523140A4 (pt) |
JP (1) | JPH05501060A (pt) |
KR (1) | KR970002669B1 (pt) |
AU (1) | AU7662091A (pt) |
BR (1) | BR9106258A (pt) |
CA (1) | CA2078659A1 (pt) |
FI (1) | FI924197A (pt) |
HU (1) | HUT62658A (pt) |
WO (1) | WO1991014436A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US5681941A (en) * | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
BR9106258A (pt) | 1990-03-21 | 1993-04-06 | Isis Pharmaceuticals Inc | Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideo |
KR970002255B1 (ko) * | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
GB9016973D0 (en) * | 1990-08-02 | 1990-09-19 | Medical Res Council | Viral growth inhibition |
JPH0813274B2 (ja) * | 1990-08-13 | 1996-02-14 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド |
US5786145A (en) * | 1990-09-20 | 1998-07-28 | Medical Research Council | Oligonucleotide competitors for binding of HIV RRE to REV protein and assays for screening inhibitors of this binding |
GB9020541D0 (en) * | 1990-09-20 | 1990-10-31 | Medical Res Council | Viral growth inhibition |
US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
DE69331543T2 (de) * | 1992-03-05 | 2002-09-26 | Isis Pharmaceutical Inc | Kovalent vernetzte oligonukleotide |
US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
US5817781A (en) | 1992-06-01 | 1998-10-06 | Gilead Sciences, Inc. | Modified internucleoside linkages (II) |
US6057093A (en) | 1992-09-28 | 2000-05-02 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
GB9622084D0 (en) * | 1996-10-23 | 1996-12-18 | Isis Innovation | Transinduction |
EP2319855B1 (en) | 1997-01-08 | 2016-04-06 | Sigma-Aldrich Co. LLC | Bioconjugation of Macromolecules |
US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
WO1999057265A1 (en) * | 1998-05-04 | 1999-11-11 | Julianna Lisziewicz | Chimeric decoy rnas having synergistic anti-hiv activity |
US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
FR2799465B1 (fr) | 1999-10-12 | 2004-02-13 | Centre Nat Rech Scient | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire |
US6995258B1 (en) * | 2000-05-25 | 2006-02-07 | City Of Hope | Nucleolar targeting of therapeutics against HIV |
EP1543158B1 (en) | 2002-07-25 | 2011-07-13 | Archemix Corp. | Regulated aptamer therapeutics |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
TR201808488T4 (tr) | 2004-02-12 | 2018-07-23 | Archemix Llc | Komplemana bağlı bozuklukların tedavisinde yararlı aptamer terapötikleri. |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
EP4082551A1 (en) | 2006-08-08 | 2022-11-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure and use of 5' phosphate oligonucleotides |
EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
JP5971948B2 (ja) * | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Vegfに対する天然アンチセンス転写物の抑制による血管内皮増殖因子(vegf)関連疾患の治療 |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68929343T2 (de) * | 1988-02-16 | 2002-09-12 | Greatbatch Gen Aid Ltd | Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen |
WO1991011535A1 (en) * | 1990-01-30 | 1991-08-08 | Childrens Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
US5874564A (en) | 1990-03-21 | 1999-02-23 | Isis Pharmaceuticals, Inc. | Reagents and methods for modulating gene expression through RNA mimicry |
BR9106258A (pt) | 1990-03-21 | 1993-04-06 | Isis Pharmaceuticals Inc | Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideo |
GB9016973D0 (en) * | 1990-08-02 | 1990-09-19 | Medical Res Council | Viral growth inhibition |
GB9020541D0 (en) * | 1990-09-20 | 1990-10-31 | Medical Res Council | Viral growth inhibition |
-
1991
- 1991-03-19 BR BR919106258A patent/BR9106258A/pt not_active Application Discontinuation
- 1991-03-19 HU HU923010A patent/HUT62658A/hu unknown
- 1991-03-19 EP EP19910907485 patent/EP0523140A4/en not_active Withdrawn
- 1991-03-19 JP JP3507270A patent/JPH05501060A/ja active Pending
- 1991-03-19 CA CA002078659A patent/CA2078659A1/en not_active Abandoned
- 1991-03-19 AU AU76620/91A patent/AU7662091A/en not_active Abandoned
- 1991-03-19 WO PCT/US1991/001822 patent/WO1991014436A1/en not_active Application Discontinuation
- 1991-06-27 US US07/724,500 patent/US5736294A/en not_active Expired - Lifetime
-
1992
- 1992-09-18 FI FI924197A patent/FI924197A/fi not_active Application Discontinuation
- 1992-09-21 KR KR92702278A patent/KR970002669B1/ko active IP Right Grant
-
1999
- 1999-02-23 US US09/255,899 patent/US6368863B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH05501060A (ja) | 1993-03-04 |
EP0523140A4 (en) | 1993-06-16 |
CA2078659A1 (en) | 1991-09-22 |
WO1991014436A1 (en) | 1991-10-03 |
FI924197A0 (fi) | 1992-09-18 |
KR970002669B1 (en) | 1997-03-07 |
KR930700117A (ko) | 1993-03-13 |
US6368863B1 (en) | 2002-04-09 |
EP0523140A1 (en) | 1993-01-20 |
US5736294A (en) | 1998-04-07 |
AU7662091A (en) | 1991-10-21 |
HUT62658A (en) | 1993-05-28 |
FI924197A (fi) | 1992-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9106258A (pt) | Processos para modular a expressao de um gene,para tratar uma doenca,um animal ou uma infeccao e para interferir com a funcao ou replicacao de um virus e oligonucleotideo ou analogo de oligonucleotideo | |
PT1061940E (pt) | Utilizacao de foliestatina para a producao de um medicamento para o tratamento de disturbios relacionados com os musculos | |
DE69001839D1 (de) | 1-hydroxyvitamin d2-epimer und dessen derivate. | |
DK0607128T4 (da) | Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker | |
ATE81978T1 (de) | Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen. | |
MX9101046A (es) | Anticuerpos novedosos para el tratamiento y prevencion de infeccion de animales y el hombre | |
PT932398E (pt) | Utilizacao do topiramento ou dos seus derivados para a producao de um medicamento para o tratamento de disturbios bipolares maniaco- depressivos | |
ES2109260T3 (es) | Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. | |
DE3776999D1 (de) | Mittel zur vorbeugung gegen pflanzenviruskrankheiten. | |
DE3681144D1 (de) | Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren. | |
NO905605L (no) | Medisinsk middel for aa behandle mastitt hos dyr og mennesker. | |
ES2139578T3 (es) | Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn. | |
EP0328924A3 (en) | Thienotriazolodiazepine compounds and pharmaceutical uses thereof | |
BR9106752A (pt) | Oligonucleotideo ou analogo de oligonucleotideo,processo para tratamento de uma infeccao por candida e processo para a modulacao da atividade de candida | |
DE68926746T2 (de) | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel | |
DK0406745T3 (da) | Antibiotiske GE 2270 faktorer A1, A2, A3 og H | |
BR9306207A (pt) | Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo | |
PT1331940E (pt) | Utilizacao da pentraxina longa ptx3 para o tratamento de doencas provocadas por uma activacao alterada do factor de crescimento fgf-2 | |
DE69007065T2 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
ES2113391T3 (es) | Factor c2a de antibiotico ge 2270. | |
DE3687233T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten. | |
IT1312090B1 (it) | Microrganismi inattivati comprendenti sostanze solubili e/osolubilizzabili ad attivita' farmacologica e/o sostanze nutrizionali | |
FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
ES2107400T1 (es) | Nueva utilizacion terapeutica de superoxidos dismutasas. | |
FR2604434B1 (fr) | Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
FC | Decision: refusal | ||
FC | Decision: refusal |